Russell Investments Group Ltd. Sells 27,724 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Russell Investments Group Ltd. cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 33.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 55,173 shares of the medical equipment provider’s stock after selling 27,724 shares during the quarter. Russell Investments Group Ltd.’s holdings in Zimmer Biomet were worth $5,034,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Chicago Partners Investment Group LLC lifted its position in shares of Zimmer Biomet by 3.3% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock valued at $376,000 after acquiring an additional 124 shares during the period. Private Trust Co. NA grew its holdings in Zimmer Biomet by 14.6% in the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock worth $98,000 after purchasing an additional 137 shares during the period. Brooklyn Investment Group increased its stake in Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Zimmer Biomet by 8.3% during the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock valued at $178,000 after purchasing an additional 149 shares during the period. Finally, Pflug Koory LLC boosted its position in shares of Zimmer Biomet by 4.9% during the 2nd quarter. Pflug Koory LLC now owns 3,866 shares of the medical equipment provider’s stock worth $353,000 after purchasing an additional 181 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ZBH. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. UBS Group decreased their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. Canaccord Genuity Group cut their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Royal Bank Of Canada decreased their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Finally, Raymond James Financial upped their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $109.00.

Zimmer Biomet Trading Up 1.1%

Shares of Zimmer Biomet stock opened at $94.22 on Friday. The company has a market capitalization of $18.67 billion, a P/E ratio of 23.32, a price-to-earnings-growth ratio of 2.45 and a beta of 0.61. The stock has a fifty day simple moving average of $96.30 and a 200 day simple moving average of $96.72. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.44. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.